| Literature DB >> 36213924 |
Shengyu Yang1, Ying Wu1, Lanfeng Sun1, Meigang Ma1, Sijie Ou1, Youshi Meng1, Jie Meng1, Chunmei Zeng1, Qi Huang1, Yuan Wu1.
Abstract
Objective: This study aimed to investigate white matter (WM) microstructural alterations and their relationship correlation with disease severity in anti-NMDA receptor (NMDAR) encephalitis. Multivariate pattern analysis (MVPA) was applied to discriminate between patients and healthy controls and explore potential imaging biomarkers.Entities:
Keywords: MRI; anti-NMDA receptor encephalitis; multivariate pattern analysis; tract-based spatial statistics; white matter
Year: 2022 PMID: 36213924 PMCID: PMC9537694 DOI: 10.3389/fpsyt.2022.997758
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 5.435
General information and clinical features of patients with anti-NMDAR encephalitis.
|
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|---|
|
|
| |||||||
| 1 | F | 29 | 1:32 | — | 12 | 4 | Glucocorticoids, IVIG | Psychiatric symptoms, seizure, decrease in level of consciousness |
| 2 | F | 33 | 1:10 | 1:10 | 5 | 5 | Glucocorticoids | Psychiatric symptoms, seizure, memory impairment, decrease in the level of consciousness, central hypoventilation |
| 3 | F | 56 | 1:10 | 1:10 | 10 | 4 | Glucocorticoids, IVIG | Psychiatric symptoms, seizure, decrease in level of consciousness |
| 4 | F | 25 | 1:32 | 1:10 | 15 | 2 | Glucocorticoids, IVIG | Psychiatric symptoms, seizure, memory impairment |
| 5 | F | 17 | 1:32 | 1:32 | 15 | 3 | Glucocorticoids, IVIG, PE | Psychiatric symptoms, seizure |
| 6 | M | 17 | 1:10 | 1:10 | 15 | 2 | Glucocorticoids | Psychiatric symptoms, seizure, involuntary movement, cognitive deficits, memory dysfunction |
| 7 | F | 16 | 1:10 | 1:10 | 13 | 3 | Glucocorticoids, IVIG | Psychiatric symptoms, language dysfunction, sleep disorders |
| 8 | M | 37 | 1:3.2 | – | 14 | 4 | Glucocorticoids | Seizure, language dysfunction |
| 9 | M | 44 | 1:1 | – | 12 | 5 | Glucocorticoids, IVIG, PE | Psychiatric symptoms, seizure, dysautonomia |
| 10 | F | 28 | 1:1 | – | 5 | 5 | Glucocorticoids | Psychiatric symptoms, seizure, decrease in level of consciousness, memory impairment |
| 11 | M | 20 | + | + | 5 | 5 | Glucocorticoids, IVIG, PE | Psychiatric symptoms, seizure, decrease in level of consciousness, central hypoventilation |
| 12 | M | 17 | 1:32 | – | 15 | 1 | Glucocorticoids, IVIG | Psychiatric symptoms, seizure, memory impairment |
| 13 | F | 21 | 1:10 | 1:100 | 13 | 4 | Glucocorticoids, IVIG | Psychiatric symptoms, seizure |
| 14 | F | 22 | + | + | 15 | 2 | Glucocorticoids | Psychiatric symptoms, seizure, involuntary movement, memory impairment |
| 15 | M | 25 | 1:32 | 1:10 | 11 | 4 | Glucocorticoids | Psychiatric symptoms, seizure |
| 16 | F | 32 | + | – | 5 | 5 | Glucocorticoids, IVIG, PE | Psychiatric symptoms, seizure, involuntary movement, language dysfunction, decreased level of consciousness, central hypoventilation |
| 17 | F | 16 | 1:10 | – | 5 | 5 | Glucocorticoids, IVIG, PE | Psychiatric symptoms, seizure, language dysfunction, decrease in level of consciousness, central hypoventilation |
| 18 | M | 19 | 1:32 | 1:320 | 15 | 4 | Glucocorticoids, IVIG, PE | Psychiatric symptoms, seizure, involuntary movement, decrease in level of consciousness, memory impairment |
| 19 | F | 49 | 1:3.2 | – | 14 | 2 | Glucocorticoids, IVIG | Psychiatric symptoms, seizure |
| 20 | M | 27 | 1:32 | 1:10 | 15 | 1 | Glucocorticoids, IVIG | Psychiatric symptoms, seizure, memory impairment |
| 21 | M | 23 | 1:1 | – | 5 | 5 | Glucocorticoids, IVIG, PE | Psychiatric symptoms, seizure, decrease in level of consciousness, central hypoventilation |
| 22 | M | 30 | 1:100 | 1:10 | 14 | 2 | Glucocorticoids | Psychiatric symptoms, seizure, language dysfunction, memory impairment |
| 23 | M | 30 | 1:32 | 1:100 | 14 | 4 | Glucocorticoids | Psychiatric symptoms, seizure, decrease in level of consciousness |
| 24 | F | 27 | 1:100 | – | 13 | 4 | Glucocorticoids | Psychiatric symptoms, seizure, decrease in level of consciousness, memory impairment |
| 25 | M | 47 | 1:10 | – | 14 | 3 | Glucocorticoids, IVIG | Psychiatric symptoms, seizure, memory impairment |
| 26 | M | 35 | 1:10 | + | 14 | 2 | Glucocorticoids, IVIG, PE | Psychiatric symptoms, seizure, language dysfunction, involuntary movement, memory impairment |
| 27 | M | 29 | + | – | 15 | 2 | Glucocorticoids | Seizure |
| 28 | F | 23 | + | – | 13 | 2 | Glucocorticoids | Psychiatric symptoms, seizure, decrease in level of consciousness. |
| 29 | F | 31 | + | – | 15 | 2 | Glucocorticoids | Psychiatric symptoms, seizure |
| 30 | M | 20 | + | – | 5 | 5 | Glucocorticoids, PE | Psychiatric symptoms, seizure, decrease in level of consciousness, central hypoventilation |
| 31 | M | 27 | 1:320 | 1:100 | 5 | 5 | Glucocorticoids, IVIG | Psychiatric symptoms, seizure, language dysfunction, movement disorders, decrease in the level of consciousness, central hypoventilation, memory |
| 32 | F | 23 | + | – | 15 | 1 | Glucocorticoids | Psychiatric symptoms, seizure, memory impairment |
NMDAR, N-methyl-d-aspartate receptor; IgG, immunoglobulin G; GCS, Glasgow Coma Scale; mRS, modified Rankin Scale; M, male; F, female; IVIG, intravenous gamma globulin; PE, plasma exchange.
Clusters with a significant between-group difference by TBSS analysis.
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|
|
|
|
| ||||
|
| ||||||
| Genu of corpus callosum | GCC | −3 | 18 | 18 | 0.0006 | 25913a |
| Body of corpus callosum | BCC | −7 | 22 | 16 | 0.0006 | 25913a |
| Splenium of corpus callosum | SCC | −10 | −28 | 26 | 0.005 | 25913a |
| Anterior limb of internal capsule R | ALIC.R | 18 | 8 | 10 | 0.005 | 25913a |
| Anterior corona radiata R | ACR.R | 26 | 28 | 7 | 0.005 | 25913a |
| Anterior corona radiata L | ACR.L | −15 | 34 | −7 | 0.0006 | 25913a |
| Superior corona radiata R | SCR.R | 24 | 3 | 19 | 0.005 | 25913a |
| Superior corona radiata L | SCR.L | −18 | 4 | 39 | 0.0006 | 25913a |
| Cingulum (cingulate gyrus) R | CGG.R | 9 | 2 | 33 | 0.006 | 25913a |
| Cingulum (cingulate gyrus) L | CGG.L | −8 | 24 | 21 | 0.002 | 25913a |
| Cingulum (hippocampus) L | CGH.R | 24 | −28 | −18 | 0.002 | 25913a |
| Retrolenticular part of internal capsule R | RLIC.R | 32 | −27 | −1 | 0.007 | 1594b |
| Fornix R | FXC.R | 32 | −14 | −12 | 0.008 | 1594b |
|
| ||||||
| Body of corpus callosum | BCC | 12 | 15 | 24 | 0.009 | 68 |
| Anterior limb of internal capsule R | ALIC.R | 22 | 20 | 5 | 0.009 | 603c |
| Anterior corona radiata R | ACR.R | 26 | 22 | 8 | 0.009 | 603c |
| Superior corona radiata R | SCR.R | 26 | −9 | 32 | 0.009 | 918 |
|
| ||||||
| Genu of corpus callosum | GCC | −14 | 29 | 17 | 0.001 | 34706d |
| Body of corpus callosum | BCC | 0 | 18 | 18 | 0.001 | 34706d |
| Splenium of corpus callosum | SCC | −18 | −49 | 18 | 0.009 | 34706d |
| Anterior limb of internal capsule R | ALIC.R | 20 | 8 | 11 | 0.002 | 34706d |
| Anterior corona radiata R | ACR.R | 24 | 21 | 10 | 0.002 | 34706d |
| Anterior corona radiata L | ACR.L | −16 | 26 | 21 | 0.001 | 34706d |
| Superior corona radiata R | SCR.R | 26 | −11 | 32 | 0.001 | 34706d |
| Cingulum (cingulate gyrus) R | CGG.R | 9 | 12 | 30 | 0.008 | 34706d |
TBSS, tract-based spatial statistics; FA, fractional anisotropy; MD, mean diffusivity; RD, radial diffusivity;
: FWE correction; a, b, c, and d indicate that these brain regions share a cluster.
Figure 1Brain regions displaying significantly altered fractional anisotropy (A), mean diffusivity (B), and radial diffusivity (C) in patients compared to controls by TBSS analysis (p < 0.01, FWE corrected). The red/yellow colors represent reduced FA in patients, while blue/light-blue colors represent increased MD and RD in patients relative to controls (color-coded according to the 1 - p-value). No significant differences in axial diffusivity were observed between the two groups. TBSS, tract-based spatial statistics.
Regions with a significant between-group difference by atlas-based analysis.
|
|
|
| |
|---|---|---|---|
|
|
| ||
| Genu of corpus callosum | GCC | 0.011 | 0.021 |
| Body of corpus callosum | BCC | 0.011 | 0.022 |
| Splenium of corpus callosum | SCC | 0.036 | 0.046 |
| Cerebral peduncle L | CBRP.L | 0.047 | ns |
| Anterior limb of internal capsule R | ALIC.R | 0.036 | ns |
| Anterior limb of internal capsule L | ALIC.L | 0.036 | 0.022 |
| Anterior corona radiata R | ACR.R | 0.036 | 0.044 |
| Anterior corona radiata L | ACR.L | 0.035 | 0.022 |
| Superior corona radiata R | SCR.R | ns | 0.021 |
| Posterior corona radiata L | PCR.L | ns | 0.039 |
| External capsule L | EC.L | ns | 0.022 |
| Cingulum (cingulate gyrus) R | CGG.R | 0.036 | 0.044 |
| Fornix R | FXC.R | 0.047 | 0.049 |
| Superior longitudinal fasciculus R | SLF.R | ns | 0.044 |
| Superior longitudinal fasciculus L | SLF.L | ns | 0.044 |
| Superior fronto-occipital fasciculus L | SFO.L | ns | 0.046 |
: FDR correction; ns, not significant.
Figure 2Metrics of the white matter in patients and controls by atlas-based analysis. Fractional anisotropy (A) and radial diffusivity (B) metrics of ICBM-DTI-81 WM label atlas, respectively. Atlas that shows a significant difference (p < 0.05 FDR correction) is marked with a “#” at the top corner. No significant differences in axial diffusivity and mean diffusivity were observed between the two groups. All abbreviations are listed in Supplementary Table 2.
Figure 3Correlation between white matter damage and GCS or mRS score in patients with anti-NMDAR encephalitis. FA, fractional anisotropy; MD, mean diffusivity; RD, radial diffusivity. All brain region abbreviations are listed in Supplementary Table 2.
MVPA classification results (10-fold cross-validation).
|
|
|
|
|
| |
|---|---|---|---|---|---|
|
|
|
|
| ||
| FA | 78.33 | 78.33 | 78.33 | 0.89 | 0.001 |
| RD | 67.71 | 65.83 | 70 | 0.81 | 0.03 |
Figure 4The ROC curves of classifier performance of FA-based (A) and RD-based (B). FA, fractional anisotropy; RD, radial diffusivity.
Figure 5The result of the MVPA classification between 32 patients and 26 controls based on FA (A) and RD (B) derived from DTI data.